Replies to post #33899 on Lexaria Bioscience Corp (LEXX)

[Shawking]

Delayed? We were promised up to 12 applied R&D programs planned for 2022, so far only one has started, HYPER-H21-4.
KELOWNA, BC / ACCESSWIRE / July 13, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the pending start of its upcoming human nicotine study NIC-H22-1. Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECHTM, leads to enhanced oral-tissue absorption and reduced negative experiences.